Featured Stories
Lundbeck's Vyepti Launch In US Disappoints In First Half
The coronavirus pandemic held back sales of Lundbeck’s newest product, Vyepti, in the US during the first half, but the company spent less than expected on SG&A because of COVID-19, and increased investments in marketing infrastructure and restructuring R&D.
The Top 10 Best-Selling Drugs of 2019
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fresh Twist: India Stays Revocation Order On Novartis Ceritinib Patent
Appellate board stays previous order that rescinded the patent on ceritinib in India, giving Novartis the upper hand for now. The spotlight is now on procedural aspects and additional evidence/submission by challenger Natco and rebuttal by the Swiss multinational.
Coronavirus Spotlight
Russia Approves First COVID-19 Vaccine
The Russian ministry of health has raised eyebrows by approving a vaccine against SARS-CoV-2 just weeks after its first clinical trials in 76 volunteers. Phase III confirmatory studies await for the adenovirus-based product but a mass vaccination plan is slated to begin in October.
Rolling Coverage Of The Coronavirus Outbreak And The Biopharma Industry's Response Is Here.
Latest News
Recent Tweets from Scrip
COVID-19 Pipeline Tracker
Product candidates in development worldwide to address the 2019-nCoV pandemic, categorized by treatment and prevention. Subscription required.
The Top 10 Best-Selling Drugs of 2019
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
COVID-19: The Race To Develop A Vaccine
The world is waiting for a coronavirus vaccine – but can we depend on it, and when will it arrive? A visual tracker of key developments from leading candidates.
The 2020 Worldwide Pharma & Biotech Industry R&D Scene
INFOGRAPHIC: A snapshot of the industry in key performance indicators, taken in early 2020.
Commercial Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Samsung BioLogics’ 'Super Plant' Reflects Robust Global COVID-19 R&D
Samsung BioLogics’ construction of a fourth, large-scale manufacturing plant reflects increasing orders amid robust global COVID-19 R&D activities and further cements the Korean firm's position as the world's biggest contract biologics producer.
Scipher Hopes IBD Alliance With Galapagos Is The First Of Many
Focused primarily on developing diagnostic tests to determine whether patients will respond to a drug, Scipher is also using the data from its artificial intelligence process to drive R&D partnerships with drug developers.
Novartis Sees Pliant’s NASH Program Offering Pathway To Treating Sickest Patients
Swiss pharma thinks targeted integrin inhibition could be part of the approach to treating cirrhotic NASH patients, those most at risk of needing a liver transplant.
Norway’s Lytix Licenses Lead Asset To Verrica For Skin Cancers
Norwegian biotech Lytix says a licensing deal with Verrica in dermatologic oncology indications gives it commercial validity – and leaves options open in other cancer areas.
Strides Hits Pause On Investments In Stelis’s Injectables
Strides has paused further investments in the sterile injectables business under Stelis, citing pandemic-related uncertainty and loss of revenue from ranitidine withdrawal in the US. A prior investment commitment of $40m in Stelis will, however, be fulfilled. Meanwhile, Strides reported a strong first quarter led by non-US markets.
Cellular Biomedicine To Go Private In Consortium Buyout
Deal Snapshot: The China/US CAR-T firm will be bought out by its management team and institutional investors in a deal structured as a merger into a new company.
Policy & Regulation Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Russia Approves First COVID-19 Vaccine
The Russian ministry of health has raised eyebrows by approving a vaccine against SARS-CoV-2 just weeks after its first clinical trials in 76 volunteers. Phase III confirmatory studies await for the adenovirus-based product but a mass vaccination plan is slated to begin in October.
Q&A: BIO CEO Michelle McMurry-Heath Outlines Diversity Goals
Expanding on difficult conversations during the recent BIO Digital meeting, the group aims to take actions that will increase diversity and inclusion in health care, science and industry.
Roche’s Evrysdi Approved For SMA, Priced Below Competitors
Risdiplam’s efficacy across two clinical trials and oral dosing made it a credible threat before its US FDA approval, but its weight-based pricing falls below Biogen’s Spinraza and Novartis’s Zolgensma.
Research & Development Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Norway’s Lytix Licenses Lead Asset To Verrica For Skin Cancers
Norwegian biotech Lytix says a licensing deal with Verrica in dermatologic oncology indications gives it commercial validity – and leaves options open in other cancer areas.
Coronavirus Update: Cheaper Remdesivir Available In India
A new cheaper version of antiviral remdesivir has been launched locally by a Indian licensee, while Chinese vaccine developers push forward with broader trials of their candidates.
Antifungal Specialist F2G Gets Near $61m Financing
A $60.8m financing round gives F2G the resources to develop what it hopes will be the first new antifungal in a new class in two decades.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.